ИНТЕГРАЦИЯ БИОМАРКЕРОВ В ПРАКТИКУ ЛЕЧЕНИЯ БОЛЬНЫХ С СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ: РОЛЬ ОПРЕДЕЛЕНИЯ УРОВНЯ НАТРИЙУРЕТИЧЕСКИХ ПЕПТИДОВ В КРОВИ
https://doi.org/10.20996/1819-6446-2017-13-6-863-870
Аннотация
В статье обсуждается роль биомаркеров для установления диагноза сердечной недостаточности в разных клинических ситуациях. Приводятся доказательные данные, ставшие основанием для применения натрийуретических пептидов при предполагаемой сердечной недостаточности. Обсуждается необходимость использования натрийуретических пептидов у больных с синдромом такоцубо. Обсуждается вопрос об ограниченной диагностической ценности использования натрийуретических пептидов у больных со сниженной функций почек, а также при других заболеваниях, при которых может увеличиваться концентрация натрийуретических пептидов в отсутствие сердечной недостаточности.
Об авторах
С. Р. Гиляревский
Российская медицинская академия непрерывного профессионального образования
Россия
Россия
Гиляревский Сергей Руджерович – доктор медицинских наук, профессор кафедры клинической фармакологии и терапии
123995, Москва, ул. Баррикадная, 2/1
М. В. Голшмид
Российская медицинская академия непрерывного профессионального образования
Россия
Россия
Голшмид Мария Владимировна – кандидат медицинских наук, доцент кафедры клинической фармакологии и терапии
123995, Москва, ул. Баррикадная, 2/1
И. М. Кузьмина
Научно-исследовательский институт скорой помощи имени Н. В. Склифосовского
Россия
Россия
Кузьмина Ирина Михайловна – кандидат медицинских наук, руководитель научного отделения неотложной кардиологии
129090, Москва, Большая Сухаревская пл., 3
Список литературы
1. Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200. doi: 10.1093/eurheartj/ehw128.
2. Roberts E., Ludman A.J., Dworzynski K., et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910. doi: 10.1136/bmj.h910.
3. Maisel A., Mueller C., Adams K., et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824-39. doi: 10.1016/j.ejheart.2008.07.014.
4. Zaphiriou A., Robb S., Murray-Thomas T., et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005;7:537-541. doi: 10.1016/j.ejheart.2005.01.022.
5. Fuat A., Murphy J.J., Hungin A.P.S., et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006;56:327-33.
6. Yamamoto K., Burnett J.C., Bermudez E.A., et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail. 2000;6:194–200. doi: 10.1054/jcaf.2000.9676
7. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349–53. doi: 10.1016/S01406736(97)06031-5.
8. Krishnaswamy P., Lubien E., Clopton P., et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001;111:274–9. doi: 10.1016/S0002-9343(01)00841-5.
9. Kelder J.C., Cramer M.J., Verweij W.M., et al. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail. 2011;17:729–34. doi: 10.1016/j.cardfail.2011.04.013.
10. Kirsch B. Electron microscopy of the atrium of the heart. Exp Med Surg 1956;14:99–111.
11. Wilkins M.R., Redondo J., Brown L.A. The natriuretic-peptide family. Lancet. 1997;349(9061):1307-10. doi: 10.1016/S0140-6736(96)07424-7.
12. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med. 1998;339(5):321-8. doi: 10.1056/NEJM199807303390507
13. Schreiber D., Schraga E.D. Natriuretic Peptides in Congestive Heart Failure. Available at: emedicine.medscape.com/article/761722-overview#a9. Checked by 11/12/2017.
14. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. N Engl J Med. 2002;347(3):161-7. doi:10.1056/NEJMoa020233.
15. Gaggin H.K., Januzzi J.L. Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832:2442-50. doi: 10.1016/j.bbadis.2012.12.014.
16. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–954. doi: 10.1016/j.amjcard.2004.12.032.
17. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–7. doi: 10.1093/eurheartj/ehi631.
18. Wright S.P., Doughty R.N., Pearl A., et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003;42:1793-800. doi: 10.1016/j.jacc.2003.05.011.
19. Yancy C.W., Jessup M., Bozkurt B., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-e161. doi: 10.1161/CIR.0000000000000509.
20. Richards A.M., Doughty R., Nicholls M.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37:1781-7. doi: 10.1016/S0735-1097(01)01269-4.
21. Tang W.H., Girod J.P., Lee M.J., et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003;108:2964-6. doi: 10.1161/01.CIR.0000106903.98196.B6.
22. Son C.S., Kim Y.N., Kim H.S., et al. Decision-making model for early diagnosis of congestive heart failure using rough set and decision tree approaches. J Biomed Inform. 2012;45:999-1008. doi: 10.1016/j.jbi.2012.04.013.
23. Kelder J.C., Cramer M.J., Van W.J., et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124:2865-73. doi: 10.1161/CIRCULATIONAHA.111.019216.
24. Balion C., Don-Wauchope A., Hill S., et al. Use of Natriuretic Peptide Measurement in the Management of Heart Failure. 13(14)-EHC118-EFed. Rockville, MD: Agency for Healthcare Research and Quality (US); 2013.
25. Booth R.A., Hill S.A., Don-Wauchope A., et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail Rev. 2014;19:439-51. doi: 10.1007/s10741-014-9445-8.
26. Anwaruddin S., Lloyd-Jones D.M., Baggish A., et al. Renal function, congestive heart failure, and aminoterminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91-7. doi: 10.1016/j.jacc.2005.08.051.
27. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976-82. doi: 10.1016/S07351097(02)02059-4.
28. Wang T.J., Larson M.G., Levy D., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90:254-8. doi: 10.1016/S0002-9149(02)02464-5.
29. Chang A.Y., Abdullah S.M., Jain T., et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol. 2007;49:109-16. doi: 10.1016/j.jacc.2006.10.040.
30. Anand I.S., Fisher E.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278-83. doi: 10.1161/01.CIR.0000054164.99881.00.
31. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392-7. doi: 10.1161/01.CIR.0000016642.15031.34.
32. Forfia P.R., Watkins S.P., Rame J.E., et al. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol. 2005;45:1667-71. doi: 10.1016/j.jacc.2005.01.046.
33. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587-93. doi: 10.1016/S0735-1097(00)00912-8.
34. Neuhold S., Huelsmann M., Strunk G., et al. Comparison of copeptin, B-type natriuretic peptide, and aminoterminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008;52:266-72. doi: 10.1016/j.jacc.2008.03.050.
35. Taub P.R., Daniels L.B., Maisel A.S. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. Heart Fail Clin. 2009;5:169-75. doi: 10.1016/j.hfc.2008.11.009.
36. van Kimmenade R.R., Pinto Y.M., Bayes-Genis A., et al. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol. 2006;98:386-90. doi: 10.1016/j.amjcard.2006.02.043.
37. Bettencourt P., Azevedo A., Pimenta J., et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-74. doi: 10.1161/01.CIR.0000144310.04433.BE.
38. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-91. doi: 10.1016/S0735-1097(00)01157-8.
39. Fonarow G.C., Peacock W.F., Horwich T.B., et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE Am J Cardiol. 2008;101:231-237. doi: 10.1016/j.amjcard.2007.07.066.
40. Logeart D., Thabut G., Jourdain P., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-41. doi: 10.1016/j.jacc.2003.09.044.
41. Maisel A., Hollander J.E., Guss D., et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328-33. doi: 10.1016/j.jacc.2004.06.015.
42. Zairis M.N., Tsiaousis G.Z., Georgilas A.T., et al. Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol. 2010; 41:284-90. doi: 10.1016/j.ijcard.2008.12.017.
43. Peacock W.F.I., De Marco T., Fonarow G.C., et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117-26. doi: 10.1056/NEJMoa0706824.
44. Lee D.S., Stitt A., Austin P.C., et al. Prediction of heart failure mortality in emergent care: a cohort study. Ann Intern Med. 2012;156:767-75. doi: 10.7326/0003-4819-156-11-20120605000003.
45. Santaguida P.L., Don-Wauchope A.C., Ali U., et al. Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Fail Rev. 2014;19:507-19. doi: 10.1007/s10741-014-9444-9.
46. Santaguida P.L., Don-Wauchope A.C., Oremus M., et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev. 2014;19:453-470. doi: 10.1007/s10741-014-9442-y.
47. Horwich T.B., Patel J., MacLellan W.R., et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833-8. doi: 10.1161/01.CIR.0000084543.79097.34.
48. Ilva T., Lassus J., Siirila-Waris K., et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail. 2008;10:772-9. doi: 10.1016/j.ejheart.2008.06.009.
49. Ledwidge M., Gallagher J., Conlon C., et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66-74. doi: 10.1001/jama.2013.7588.
50. Huelsmann M., Neuhold S., Resl M., et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J. Am Coll Cardiol. 2013;62:1365-72. doi: 10.1016/j.jacc.2013.05.069.
51. Wessler B.S., Kramer D.G., Kelly J.L., et al. Drug and device effects on peak oxygen consumption, 6minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. Circ Heart Fail. 2011;4:578-88. doi: 10.1161/CIRCHEARTFAILURE.111.961573.
52. Packer M., McMurray J.J.V., Desai A.S., et al., PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54-61. doi: 10.1161/CIRCULATIONAHA.114.013748
53. Savarese G., Musella F., D’Amore C., et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol HF. 2014;2:148-58. doi: 10.1016/j.jchf.2013.11.007.
54. Olivier A., Girerd N., Michel J.B., et al. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Int J Cardiology. 2017;241:344-50. doi: 10.1016/j.ijcard.2017.02.018.
55. Udelson J.E., Feldman A.M., Greenberg B., et al. Randomized, double-blind, multicenter, placebocontrolled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010;3:347-53. doi: 10.1161/CIRCHEARTFAILURE.109.906909.
56. Madhavan M., Borlaug B.A., Lerman A., et al. Stress hormone and circulating biomarker profile of apical ballooning syndrome (Takotsubo cardiomyopathy): insights into the clinical signifcance of B-type natriuretic peptide and troponin levels. Heart. 2009;95:1436-41. doi: 10.1136/hrt.2009.170399.
57. Ahmed K.A., Madhavan M., Prasad A. Brain natriuretic peptide in apical ballooning syndrome (Takotsubo/stress cardiomyopathy): comparison with acute myocardial infarction. Coron Artery Dis. 2012;23:259-64. doi: 10.1097/MCA.0b013e3283526a57.
58. Frohlich G.M., Schoch B., Schmid F., et al. Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy. Int J Cardiol. 2012;154:328-32. doi: 10.1016/j.ijcard.2011.09.077
59. Nguyen T.H., Neil C.J., Sverdlov A.L., et al. N-terminal pro-brain natriuretic protein levels in takotsubo cardiomyopathy. Am J Cardiol. 2011;108:1316-21. doi: 10.1016/j.ijcard.2011.09.077.
60. Lyon A.R., Bossone E., Schneider B., et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18:8-27. doi: 10.1002/ejhf.424.
61. Janda S., Swiston J. Diagnostic accuracy of pleural fluid NT-pro-BNP for pleural effusions of cardiac origin: a systematic review and meta-analysis. BMC Pulm Med. 2010;10:58. doi: 10.1186/14712466-10-58. doi: 10.1186/1471-2466-10-58.
Рецензия
Для цитирования:
Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. ИНТЕГРАЦИЯ БИОМАРКЕРОВ В ПРАКТИКУ ЛЕЧЕНИЯ БОЛЬНЫХ С СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ: РОЛЬ ОПРЕДЕЛЕНИЯ УРОВНЯ НАТРИЙУРЕТИЧЕСКИХ ПЕПТИДОВ В КРОВИ. Рациональная Фармакотерапия в Кардиологии. 2017;13(6):863-870. https://doi.org/10.20996/1819-6446-2017-13-6-863-870
For citation:
Gilyarevskiy S.R., Golshmid M.V., Kuzmina I.M. INTEGRATION OF BIOMARKERS INTO THE PRACTICE OF TREATING PATIENTS WITH HEART FAILURE: THE ROLE OF DETERMINING THE BLOOD LEVEL OF NATRIURETIC PEPTIDES. Rational Pharmacotherapy in Cardiology. 2017;13(6):863-870. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-6-863-870
Просмотров:
574
Послать статью по эл. почте 